These insights were further validated in three independent BLCA cohorts (Figures S8f, S9f, S10f), reinforcing the clinical relevance of FAM174B as both a predictive biomarker and potential therapeutic target in BLCA. The gene discussed is FAM174B; the disease is bladder transitional cell carcinoma.